To further study the role of SPHK in CLL, we herein determine whether SPHK inhibitors can reduce the emergence of in vitro venetoclax resistance in CLL cells and/or are able to induce the cell death of already venetoclax-resistant cells. Here, SPHK1 is linked to B-cell chronic lymphocytic leukemia.